Biotech News

BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application

BioCardia (BCDA)BioCardiaFDA / regulatory

BioCardia®, Inc. (NASDAQ: BCDA) , a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has completed the process with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) concerning the application materials required to obtain regulatory approval in Japan for its CardiAMP Cell Therapy System ("CardiAMP") for the treatment of ischemic heart failure.

Related news

BioCardia

Cardiovascular Cell Therapy Company BioCardia develops cellular and cell-derived therapies for cardiovascular and pulmonary diseases. Its platform includes autologous CardiAMP and allogeneic CardiALLO cell therapies, supported by the Helix delivery and Morph vascular-navigation technologies. CardiAMP Heart Failure Program CardiAMP Cell...

Recent company news

Stock data

Close
0.77 USD
Market cap
10.24M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States